New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort

Cancer Biology and Therapy

Volumn 12, Issue 11, 2011, Pages 997-1004

  Nam, Robert K ^a   Zhang, William ^a   Siminovitch, Katherine ^b   Shlien, Adam ^a   Kattan, Michael W ^c   Klotz, Laurence H ^a   Trachtenberg, John ^c   Lu, Yan ^b   Zhang, Jinyi ^b   Yu, Changhong ^c   Toi, Ants ^c   Loblaw, D Andrew ^d   Venkateswaran, Vasundara ^a   Stanimirovic, Aleksandra ^a   Sugar, Linda ^d   Malkin, David ^a   Seth, Arun ^a   Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b University Health Network   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; CHROMOSOME 10Q; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 15Q; CLINICAL ASSESSMENT; COHORT ANALYSIS; GENE FREQUENCY; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BIOPSY; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 15; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 82755195732     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.11.18366     Document Type: Article

References (22)

1. Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Hum Genet 1998; 62:653-8; PMID:9497242; http://dx.doi.org/10.1086/301745
2. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-7; PMID:17401366; http://dx.doi.org/10.1038/ng1999
3. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39:645-9; PMID:17401363; http://dx.doi.org/10.1038/ ng2022
4. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009; 15:3223-30; PMID:19366828; http://dx.doi.org/10.1158/1078-0432. CCR-08-2733
5. Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, Gronberg H, et al. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 2009; 18:1659-62; PMID:19423541; http://dx.doi.org/10.1158/1055-9965.EPI-08-1148
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-24; PMID:12824459; http://dx.doi.org/10.1056/NEJMoa030660
7. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350:2239-46; PMID:15163773; http://dx.doi.org/10.1056/NEJMoa031918
8. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969-74; PMID: 9749478; http://dx.doi.org/10. 1001/jama.280.11.969
9. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58-64; PMID:4813554
10. Barry MJ, Fowler FJJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148:1549-57; PMID:1279218
11. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-9; PMID:16862161; http://dx.doi.org/10.1038/ng1847
12. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358:910-9; PMID:18199855; http://dx.doi.org/10.1056/NEJMoa075819
13. Harrell FE. Regression modeling strategies with applications to linear models. In: Logistic Regression, and Survival Analysis. New York: Springer-Verlag 2001.
14. Kraft P, Wacholder S, Cornelis MC, Hu FB, Hayes RB, Thomas G, et al. Beyond odds ratios-communicating disease risk based on genetic profiles. Nat Rev 2009; 10:264-9.
15. Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, et al. Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. Clin Cancer Res 2009; 15:1787-93; PMID: 19223501; http://dx.doi.org/10.1158/1078-0432.CCR-08-1593
16. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009. In press. PMID:19434657; http://dx.doi.org/10.1002/pros.20970
17. Kraft P. Curses - winner's and otherwise - in genetic epidemiology. In: Epidemiology. Cambridge, Mass 2008:649-51; discussion 57-8.
18. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33:177-82; PMID:12524541; http://dx.doi.org/10.1038/ng1071
19. Chernova OB, Hunyadi A, Malaj E, Pan H, Crooks C, Roe B, et al. A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells. Oncogene 2001; 20:5378-92; PMID:11536051; http://dx.doi.org/10.1038/sj.onc.1204694
20. Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, et al. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 2008; 29:2341-6; PMID:18845558; http://dx.doi.org/10.1093/carcin/bgn235
21. Nam RK, Toi A, Trachtenberg J, Jewett MA, Klotz L, Fleshner N, et al. Variation in patterns of practice in diagnosing screen-detected prostate cancer. BJU Int 2004; 94:1239-44; PMID:15610097; http://dx.doi.org/10.1111/j.1464-410X. 2004.05150.x
22. Presti JC, Jr. Prostate biopsy strategies. Nat Clin Pract Urol 2007; 4:505-11; PMID:17823604; http://dx.doi.org/10.1038/ncpuro0887